1329836-90-9
1329836-90-9
Chemical Structure
Pravastatin-d3 sodium
- CAS No.: 1329836-90-9
- Formula:C23H32D3NaO7
- Molecular Weight:449.53
IUPAC Name: sodium (3R,5R)-3,5-dihydroxy-7-((1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-(((S)-2-(methyl-d3)butanoyl)oxy)-1,2,6,7,8,8a-hexahydronaphthalen-1-yl)heptanoate
InChIKey: VWBQYTRBTXKKOG-ZJDKIXRVSA-M
SMILES: O=C([C@H](CC)C([2H])([2H])[2H])O[C@H]1C[C@@H](C=C2[C@]1([C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC([O-])=O)O)O)[H])O.[Na+]
Biological Activity: Pravastatin-d3 (sodium) is the deuterium labeled Pravastatin sodium salt. Pravastatin (CS-514) sodium salt is a competitive HMG-CoA reductase inhibitor against sterol synthesis with IC50 of 5.6 μM[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Pravastatin-d3 sodium | Pravastatin-d3 (sodium) is the deuterium labeled Pravastatin sodium salt. Pravastatin (CS-514) sodium salt is a competitive HMG-CoA reductase inhibitor against sterol synthesis with IC50 of 5.6 μM. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Pravastatin sodium (Standard) | 98.10% | Pravastatin (sodium) (Standard) is the analytical standard of Pravastatin (sodium). This product is intended for research and analytical applications. Pravastatin sodium (CS-514 sodium) is an HMG-CoA reductase inhibitor against sterol synthesis with IC50 of 5.6 μM. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Pravastatin-13C,d3 sodium | Pravastatin-13C,d3 (sodium) is the 13C- and deuterium labeled Pravastatin (sodium). Pravastatin sodium (CS-514 sodium) is an HMG-CoA reductase inhibitor against sterol synthesis with IC50 of 5.6 μM. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Pravastatin sodium | 99.02% | Pravastatin sodium (CS-514 sodium) is an HMG-CoA reductase inhibitor against sterol synthesis with IC50 of 5.6 μM. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. McTavish D, et al. Pravastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs. 1991 Jul;42(1):65-89. [Content Brief]
